Inotuzumab Ozogamicin (IO) and Donor Lymphocyte Infusion (DLI) are a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

被引：0
|
作者：
Papayannidis, Cristina [1 ]
Sartor, Chiara [2 ]
Dominietto, Alida [3 ]
Zappone, Elisabetta [4 ]
Marconi, Giovanni [2 ]
Abbenante, Maria Chiara [5 ]
Parisi, Sarah [2 ]
Robustelli, Valentina [2 ]
Terragna, Carolina [1 ]
Nanni, Jacopo [2 ]
Soverini, Simona [2 ]
Cristiano, Gianluca [2 ]
Arpinati, Mario [1 ]
Paolini, Stefania [1 ]
Martinelli, Giovanni [6 ]
Curti, Antonio [1 ]
Cavo, Michele [2 ]
Bonifazi, Francesca [1 ]
机构：
[1] Azienda Osped Univ St Orsola Malpighi, Ist Ematol, Bologna, Italy
[2] Univ Bologna Osped St Orsola Malpighi, Ist Ematol Seragnoli, Bologna, Italy
[3] IRCCS Osped Policlin San Martino, Genoa, Italy
[4] AOUS Siena, Policlin Scotte, UOC Ematol, Siena, Italy
[5] UOC Ematol, Casa Cura Sollievo Sofferenza, San Giovanni Rotondo, Italy
[6] IRST Ist Sci Romagnolo Cura & Studio Tumori, Meldola, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
acute lymphoblastic leukemia; ALL; inotuzumab ozogamicin; donor lymphocyte infusion;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ALL-073
引用
收藏
页码：S161 / S161
页数：1
相关论文
共 50 条
  • [1] Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant
    Papayannidis, Cristina
    Sartor, Chiara
    Dominietto, Alida
    Zappone, Elisabetta
    Arpinati, Mario
    Marconi, Giovanni
    Cristiano, Gianluca
    Nanni, Jacopo
    Parisi, Sarah
    Barbato, Francesco
    Paolini, Stefania
    Soverini, Simona
    Terragna, Carolina
    Robustelli, Valentina
    Testoni, Nicoletta
    Chirumbolo, Gabriella
    Curti, Antonio
    Cavo, Michele
    Bonifazi, Francesca
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) : 580 - 583
  • [2] INOTUZUMAB OZOGAMICIN AND DONOR LYMPHOCYTE INFUSION ARE A SAFE AND PROMISING COMBINATION IN RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC TRANSPLANT
    Papayannidis, C.
    Sartor, C.
    Dominietto, A.
    Zappone, E.
    Marconi, G.
    Abbenante, M. C.
    Parisi, S.
    Robustelli, V.
    Terragna, C.
    Nanni, J.
    Cristiano, G.
    Arpinati, M.
    Paolini, S.
    Curti, A.
    Cavo, M.
    Bonifazi, F.
    HAEMATOLOGICA, 2020, 105 : S91 - S91
  • [3] Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL)
    Kebriaei, Partow
    Wilhelm, Kaci
    Ravandi, Farhad
    Saliba, Rima M.
    De Lima, Marcos
    Ciurea, Stefan O.
    Worth, Laura L.
    O'Brien, Susan
    Thomas, Deborah A.
    Champlin, Richard
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1340 - 1341
  • [4] Inotuzumab ozogamicin and DLI can induce molecular remission in acute lymphoblastic leukemia relapse after allogeneic HSCT
    Steinmann, J.
    Berg, T.
    Jedlickova, Z.
    Ajib, S.
    Farshi, P.
    Riemann, J.
    Lang, F.
    Serve, H.
    Goekbuget, N.
    Bug, G.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S169 - S170
  • [5] Concurrent Use of Blinatumomab and Donor Lymphocyte Infusion (DLI) for Treatment of Relapsed Precursor B Cell Acute Lymphoblastic Leukemia (pre B ALL) after Allogeneic Hematopoietic Cell Transplant (HCT)
    Ueda, Masumi
    Lazarus, Hillard M.
    Tomlinson, Benjamin
    Creger, Richard
    Kolk, Merle
    de Lima, Marcos
    Cooper, Brenda
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S359 - S360
  • [6] Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Marks, David, I
    Kebriaei, Partow
    Stelljes, Matthias
    Goekbuget, Nicola
    Kantarjian, Hagop
    Advani, Anjali S.
    Merchant, Akil
    Stock, Wendy
    Cassaday, Ryan D.
    Wang, Tao
    Zhang, Hui
    Loberiza, Fausto
    Vandendries, Erik
    DeAngelo, Daniel J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (09) : 1720 - 1729
  • [7] A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation
    Izumi, Akihiko
    Tachibana, Takayoshi
    Ando, Taiki
    Tanaka, Masatsugu
    Kanamori, Heiwa
    Nakajima, Hideaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (01) : 69 - 76
  • [8] A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation
    Akihiko Izumi
    Takayoshi Tachibana
    Taiki Ando
    Masatsugu Tanaka
    Heiwa Kanamori
    Hideaki Nakajima
    International Journal of Hematology, 2022, 115 : 69 - 76
  • [9] Donor lymphocyte infusion(DLI) in relapsed, hematologic malignancies after allogeneic stem cell transplantation.
    Lee, KE
    Jung, CW
    Kim, M
    Lee, MH
    Park, K
    Kim, DY
    Yoon, SS
    Park, SA
    Kim, BK
    BLOOD, 2002, 100 (11) : 453B - 453B
  • [10] Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Kebriaei, Partow
    Stelljes, Matthias
    DeAngelo, Daniell J.
    Gokbuget, Nicola
    Kantarjian, Hagop
    Advani, Anjali S.
    Merchant, Akil
    Stock, Wendy
    Wang, Tao
    Zhang, Hui
    Loberiza, Fausto R.
    Vandendries, Erik
    Marks, David I.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S52 - S53
12345